Skip to main content
Almirall S.A. logo

Almirall S.A. — Investor Relations & Filings

Ticker · ALM ISIN · ES0157097017 LEI · 95980020140005007996 MC Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2024-07-22 Earnings Release
Country ES Spain
Listing MC ALM

About Almirall S.A.

http://www.almirall.com

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Recent filings

Filing Released Lang Actions
Almirall remite presentación sobre los Resultados del primer semestre de 2024
Earnings Release Classification · 98% confidence The document is titled "1S 2024 Resultados financieros & Business Update" and contains detailed financial highlights for the first half (1S) of 2024, including Net Sales (€497.2 M), EBITDA (€104.5 M), and specific product performance (Ilumetri®, Ebglyss®). It also includes an agenda featuring the CFO discussing 'Evolución financiera' and a dedicated section titled 'Evolución financiera'. This structure, focusing on comprehensive financial performance for a defined interim period (six months), strongly indicates an Interim/Quarterly Report, which corresponds to the 'IR' code. It is too detailed to be just an Earnings Release (ER) and is not the full annual report (10-K). H1 2024
2024-07-22 Spanish
Operaciones del contrato de liquidez durante el segundo trimestre de 2024
Transaction in Own Shares Classification · 99% confidence The document is titled "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information) and explicitly states it is a communication to the CNMV (Comisión Nacional del Mercado de Valores, the Spanish securities market regulator) regarding operations conducted under a liquidity contract (market making agreement). The content details the number of shares bought and sold, cash involved, and provides a detailed daily breakdown of these transactions for the period April 1, 2024, to June 30, 2024. This type of filing, reporting transactions in the company's own shares (buybacks/sales under a liquidity contract), directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a report publication announcement (RPA) as it contains the substantive data, not just a notice of publication.
2024-07-16 Spanish
Información sobre dividendos
Notice of Dividend Amount Classification · 99% confidence The document text is titled "Información sobre dividendo" (Dividend Information) and explicitly communicates the admission to trading of new shares issued as a consequence of the company's flexible dividend system ("sistema de dividendo flexible"). This directly relates to the distribution of profits to shareholders via shares, which falls under the definition of a dividend announcement. The specific code matching this action is 'DIV' (Notice of Dividend Amount). Although it mentions capital increase consequences, the primary context is the dividend distribution mechanism.
2024-06-12 Spanish
La FDA de EEUU aprueba la extensión de tratamiento de Klisyri® (tirbanibulina) de Almirall, en cara o cuero cabelludo con queratosis actínica
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement dated June 10, 2024, from Almirall, S.A., titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It explicitly states that it is being issued 'en cumplimiento de lo dispuesto en la Ley del Mercado de Valores' (in compliance with the Securities Market Law). The content details a specific regulatory event: the US FDA approval of an extended treatment indication for the drug Klisyri®. This type of material, announcing a significant, non-financial regulatory or operational event that is material to investors, typically falls under general regulatory announcements or news releases that don't fit the highly specific categories like 10-K, ER, or DIV. Since it is a formal, material announcement that doesn't fit the other specific categories (like M&A, Capital Change, or Director Dealing), the most appropriate classification is the general regulatory filing/announcement category, RNS (Regulatory Filings). The document length is short (2661 chars), but it is the primary announcement itself, not just a notice that a report is attached, thus ruling out RPA.
2024-06-10 Spanish
Información sobre dividendo
Notice of Dividend Amount Classification · 98% confidence The document is titled "Información sobre dividendo" (Dividend Information) and details the outcome of a flexible dividend system involving a free capital increase, the percentage of shareholders who opted for new shares, the resulting capital structure changes, and the timeline for listing the new shares. This content directly relates to the announcement of dividend details and the resulting capital structure adjustments. The most specific category is 'Notice of Dividend Amount' (DIV). Although it involves capital changes, the primary focus is communicating the result of the dividend election process.
2024-06-05 Spanish
Almirall remite presentación sobre los Resultados del primer trimestre de 2024
Earnings Release Classification · 98% confidence The document is titled "1T 2024 Resultados financieros & Business Update" (1Q 2024 Financial Results & Business Update) and contains detailed financial figures for the first quarter (1T 2024), including Sales, EBITDA, R&D expenses, and a breakdown of sales by product and geography. It explicitly discusses financial evolution ('Evolución financiera') and provides key highlights for the period. This structure is characteristic of a company reporting its periodic financial performance, which aligns best with an Interim/Quarterly Report (IR). While it contains elements of an Earnings Release (ER) by providing highlights, the depth of the financial tables and management discussion suggests it is the comprehensive quarterly report rather than just the initial press release. Q1 2024
2024-05-13 Spanish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.